Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders
March 08, 2021 at 05:21 pm EST
Share
On March 3, 2021, Evan Jones, a director of OpGen, Inc. (the Company) since 2010, notified the Chairman of the Board of Directors of the Company that, for personal reasons, he would not stand for re-election at the 2021 Annual Meeting of Stockholders of the Company (the 2021 Annual Meeting). Mr. Jones' resignation was not the result of any disagreement with the Company or its management with respect to any matter relating to the Company's operations, policies or practices.
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
OPGEN, INC. 